Shukra Pharmaceuticals Declares Unaudited Q2 FY27 Results

Shukra Pharmaceuticals Ltd announced its unaudited financial results for the quarter and half-year ended September 30, 2026. The Board of Directors approved these results, along with the limited review reports from the statutory auditors. The company operates in two segments: Shukra Pharmaceutical and Shukra MedTech. During the half-year, convertible warrants were converted into equity shares, increasing the company's equity share capital. The company also reported a change in its name from Shukra Pharmaceuticals Limited to Shukra Medtech Limited, effective October 12, 2026.